Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists, which work by stimulating/activating/enhancing the r… Read More

Emerging in the field of excess body fat management, retatrutide represents a distinct approach. Unlike many current medications, retatrutide functions as a twin agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) sensors. This simultaneous stimulation promotes multiple advan… Read More